Etrials Restructuring—Again

Monday, December 22, 2008 11:13 AM

A month after naming a new permanent CEO, beleaguered eClinical company etrials is reorganizing its management structure—a move that will result in the departure of once-interim CEO Chuck Piccirillo as well as two other senior executives.

This is the second major management restructuring for etrials in 2008. Earlier this year, the company lost its CEO, chief financial officer, and chief operating officer (whose position was eliminated).

Piccirillo served as CEO from July to November while the company launched an executive search to replace Chip Jennings, who resigned suddenly in July. Piccirillo was replaced by permanent CEO M. Denis Connaghan in November and resumed his position as vice president of technology.

The reorganization, according to a company statement, is intended to better align operations with customer need and more effectively leverage strengths. However, the announcement comes after more than a year of financial struggle for the Morrisville, N.C.-based company.

In November, etrials reported a $6.1-million net loss for the third quarter. The company’s share prices have dropped almost 70% since the start of the year to $0.84 in morning trading.

Share:          
CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs